AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: SueWallSt

Core Viewpoint - The article discusses the significant decline in Aquestive Therapeutics, Inc. (AQST) stock following a downgrade by Cantor, which reduced its price target from $15 to $8 due to concerns over the FDA's review process for Anaphylm, leading to potential delays and substantial investor losses [1][6]. Group 1: Stock Performance and Analyst Reactions - AQST shares fell from $6.21 to $3.91, a loss of $2.30 per share, after the FDA identified deficiencies in the Anaphylm NDA [2]. - Analysts had previously built their models on management's assurances of a timely FDA approval, which were later contradicted by the FDA's findings [2][3]. - The rapid reassessment by analysts following the January 9 disclosure highlights a critical disconnect between management's portrayal of the FDA review and the actual deficiencies identified by the FDA [3][5]. Group 2: Implications for Investors - The downgrades by analysts reflect the market's reliance on management's statements regarding FDA progress, which were later proven inconsistent, resulting in significant losses for investors [4][5]. - Oppenheimer's report indicated that the situation could lead to a stock price below cash value, depending on the FDA's actions, emphasizing the severity of the setback [6].